Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty

计划入组 250 人 · 首次发布于 2021 年 1 月 22 日

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

首次发布于 2009 年 12 月 9 日

Evaluation of an Educational Intervention on Antibiotics in Dental Care

计划入组 3,498 人 · 首次发布于 2025 年 6 月 11 日

USP1 inhibitor(Shanghai Impact)

CX-1796

thalassemia therapeutics

IMPACT APPLICATIONS, INC.

United States

IMPACT Biotech Ltd

Israel

JASPER THERAPEUTICS, INC

United States

IMPACT Therapeutics Licenses PARP Inhibitor Senaparib to Pharmanovia in Deal Worth Up to €423.5 Million

Senaparib Approved in China for First-Line Maintenance Therapy in Ovarian Cancer

FDA Rejects Applied Therapeutics' Govorestat for Galactosemia, Citing Clinical Application Deficiencies